Aging Populations And AI Will Accelerate Gene Therapy Adoption
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 10 Analysts
Published
18 May 25
Updated
08 Aug 25
AnalystHighTarget's Fair Value
US$252.00
40.4% undervalued intrinsic discount08 Aug
US$150.27
1Y
-24.4%7D
9.3%